Conmed (CNMD) EBITDA (2010 - 2026)

Conmed has reported EBITDA for 17 years, with the latest figure at $15.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 105.79% year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.6 million (down 39.23% YoY), and the FY2025 full-year result was $59.6 million, down 51.82% from the prior year.
• EBITDA for Q1 2026 stood at $15.4 million, down from $19.7 million in the prior quarter.
• The five-year high for EBITDA was $48.7 million in Q3 2024, with the low at -$172.6 million in Q2 2022.
• Historically, EBITDA has averaged $11.0 million across 5 years, with a median of $19.7 million in 2025.
• Annual changes were most pronounced in 2022 — EBITDA sank 1072.98% — and 2024, when it soared 327.65%.
• Conmed's EBITDA stood at $28.9 million in 2022, then advanced by 27.72% to $36.9 million in 2023, then declined by 19.66% to $29.6 million in 2024, then slumped by 33.56% to $19.7 million in 2025, then retreated by 21.55% to $15.4 million in 2026.
• The last three EBITDA figures came in at $15.4 million (Q1 2026), $19.7 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.